Form 4: Kineta Director Bartoszek Acquires Shares to Settle Financing Dispute

Raymond Bartoszek, a director of Kineta, Inc., acquired 903,995 shares of common stock at $0.5531 per share to settle a dispute with RLB Holdings Connecticut, LLC regarding a prior financing agreement.

Summary

• Raymond J. Bartoszek, a director of Kineta, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 1, 2024, Bartoszek acquired 903,995 shares of Kineta's common stock at a price of $0.5531 per share.
• The acquisition was made pursuant to a Settlement Agreement and Mutual Release entered into on April 22, 2024, between Kineta and RLB Holdings Connecticut, LLC.
• The settlement resolves potential claims related to RLB's failure to purchase $2,500,000 of Kineta's common stock under a previous financing agreement.
• Following the transaction, Bartoszek directly owns 17,206 shares and indirectly owns 1,748,473 shares through RLB Holdings Connecticut, LLC.
• Bartoszek also indirectly owns 1,001 shares through his son and 1,000 shares through his daughter.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the settlement resolves a dispute, it also highlights a prior failure in securing financing. The impact on the company's future prospects is uncertain.

Positives

• The settlement resolves a dispute with RLB Holdings Connecticut, LLC, removing potential legal uncertainty.
• Kineta receives shares in lieu of the previously agreed upon financing, which could be seen as a positive resolution to a potentially negative situation.

Negatives

• The settlement indicates a prior failure by RLB Holdings Connecticut, LLC to fulfill a $2,500,000 financing agreement, which could raise concerns about the company's financial stability or investor confidence.

Risks

• The settlement agreement may not fully compensate Kineta for the initial failure of RLB Holdings Connecticut, LLC to purchase the agreed-upon shares.
• The market's reaction to the settlement and the issuance of new shares could negatively impact Kineta's stock price.

Future Outlook

The document does not contain specific forward-looking statements or guidance.

Industry Context

Settlements of financing disputes are not uncommon in the biotech industry, especially for smaller companies that rely on private placements and other forms of alternative financing. The specific terms of the settlement will be scrutinized by investors to assess the impact on Kineta's financial position and future prospects.

Comparison to Industry Standards

• It's difficult to compare this specific settlement to industry standards without knowing the exact details of the original financing agreement and the reasons for its failure.
• Similar situations can be seen with companies like Ocugen, Inc. and Vaxart, Inc., which have also relied on private placements and faced challenges in securing funding.
• The key factor is whether the settlement is viewed as a favorable outcome for Kineta compared to the potential costs and risks of litigation.

Stakeholder Impact

• Shareholders may be concerned about the initial failure of the financing agreement and the potential dilution from the issuance of new shares.
• The settlement could impact investor confidence in the company's ability to secure funding.

Key Dates

Keywords

Kineta, Bartoszek, RLB Holdings Connecticut LLC, Settlement Agreement, Beneficial Ownership, Form 4, Financing Agreement, Shares